# Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer

> **NCT07065630** · PHASE2 · RECRUITING · sponsor: **University of Chicago** · enrollment: 38 (estimated)

## Conditions studied

- Head and Neck Cancer
- HPV

## Interventions

- **DRUG:** Volrustomig
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT07065630
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-07
- **Primary completion:** 2029-08-13
- **Final completion:** 2029-08-13
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2026-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07065630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07065630, "Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07065630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*